OBJECTIVES:
To analyze the effectiveness of a multicomponent home-based environmental asthma intervention targeting children from low income families in East Harlem, New York City. METHODS: Three hundred eighty children aged 17 years or younger with asthma participated in the study. These children and their families were assessed for baseline characteristics including asthma symptoms and health care utilization experienced by a child; presence of home environmental triggers; and parents' knowledge and skills in managing the child's asthma. Based on baseline characteristics, families that received environmental intervention (n=200) were compared with those that did not (n=18). The main asthma outcomes were rates of emergency department visits (edv), hospitalizations (hsp), asthma symptom days (asd), school days missed (sdm), and work days missed (wdm) due to asthma. Observable variables included age, gender, race, and baseline rates of edv, hsp, asd, sdm, and wdm. The effect of the intervention was measured as the difference in the main asthma outcomes at the baseline and at post-intervention assessment. To reduce the influence of confounding factors we applied propensity score method to estimate effect of the intervention on the main asthma outcomes. RESULTS: Baseline main asthma outcomes were: 2.56 (intervention group) and 2.64 (control group) for edv, 0.44 and 0.62 for hsp, 7.35 and 5.86 for asd, 5.38 and 6.96 for sdm, and 6.95 and 3.57 for wdm. The average treatment effect of the intervention was 2.13 for edv, 0.92 for hsp, 2.67 for asd, 1.95 for sdm, and 1.89 for wdm. All estimates, except hospitalizations, were significant. The unmatched outcomes for the same outcomes were 3.36, -0.17, 3.80, 1.66, and 1.48 respectively. CONCLUSIONS: The results of the study suggest that low-income families can benefit from the intervention by reducing emergency department visits, asthma symptom days, and missed school and work days.
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EVALUATION OF ASTHMA-RELATED PHARMACY QUALITY ALLIANCE (PQA) MEASURES IN THE MISSISSIPPI MEDICAID POPULATION
Datar M 1 , Null KD 1 , Hardwick SP 2 , Clark JP 2 1 University of Mississippi, University, MS, USA, 2 Mississippi Division of Medicaid, Jackson, MS, USA OBJECTIVES: The National Quality Forum (NQF) has endorsed measures from the Pharmacy Quality Alliance (PQA) for suboptimal asthma control (SAC) and absence of controller therapy (ACT) to measure the quality of care among asthma beneficiaries. The purpose of this study was to evaluate a baseline for the Mississippi Division of Medicaid using the PQA measures. METHODS: A retrospective cross-sectional analysis of 2008-2012 Mississippi Medicaid claims was undertaken. Asthma beneficiaries aged 5 -50 years as of the last day of each measurement year were identified. The inclusion and exclusion criteria were applied according to the PQA measure specifications, with an expanded age inclusion to account for Medicaid's pediatric population. Beneficiaries with at least 3 canisters of short-acting beta agonists within 90 days were identified as those with SAC. Of SAC beneficiaries, those who did not receive controller therapy including inhaled steroids, long-acting beta agonists, and leukotriene inhibitors in the same 90 day period were defined as those with ACT. Costs were compared between ACT and non-ACT beneficiaries for each measurement year. RESULTS: A total of 62,557 beneficiaries were identified from 2008 to 2012. The percentage of asthma beneficiaries having SAC along with ACT decreased from 8.08% (2008) to 5.15% (2012). Beneficiaries with ACT (compared to non-ACT beneficiaries) had significantly higher asthma-related total costs [$1,516.98 vs. $593.66 (2008) ; $1,571.98 versus $648.78 (2009); $1,586.06 versus $664.36 (2010); $1,748.73 versus $722.36 (2011); $1,750.64 versus $709. 63 (2012) ]. Cost differences between the two groups for all the years was significant (p<0.01). CONCLUSIONS: This study of an expanded SAC/ACT measure in a Medicaid population found that the proportion of ACT beneficiaries has consistently decreased since 2008; providing a baseline measure for future interventions. Since beneficiaries with ACT have higher costs than non-ACT beneficiaries, further decline in the numbers for this population is needed in the coming years. 
PRS51 SMOKING IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS: SOCIO-DEMOGRAPHIC FACTORS ASSOCIATED WITH SMOKING CESSATION
OBJECTIVES:
Smoking is one of the major risk factors in chronic obstructive pulmonary disease (COPD) patients, with 90% of deaths from COPD being attributable to smoking. According to the Centers for Disease Control and Prevention (CDC), smoking cessation reduces the risk of developing COPD. Still, little is known about the use of smoking cessation agents and the factors that affect their use among patients. The purpose of the study is to identify the sociodemographic factors that affect the use of these agents among COPD patients. METHODS: A retrospective study was done to identify smokers having COPD (ICD9:490-496) and those who use smoking cessation agents from 2006-2010 using Medical Expenditure Panel Survey (MEPS) data. A multiple logistic regression model was built to identify significant socio-demographic predictors associated with the use of smoking cessation agents. RESULTS: Out of 2218 smokers with COPD, 176 reported use of smoking cessation agents during the 5 year period. Logistic regression showed African Americans were less likely to use smoking cessation agents than Caucasians (OR=0.379, 95% CI 0.208-0.688), patients having public insurance were more likely to report use of these agents than other insurances (OR=2.619, 95% CI 1.265-5.422), and patients with higher educational levels (OR=1.127, 95% CI 1.043-1.217) were more likely to use these agents. CONCLUSIONS: Results showed that a large number of patients continued to smoke even after the diagnosis of COPD whereas; only 176 patients (8%) used smoking cessation agents. Race, educational level, and insurance status were significant predictors of smoking cessation agents' use. Further research needs to be done to evaluate reasons for minimal use of these agents in COPD patients. Results showed inconsistent use of these agents among different population groups; hence there is a requirement for need based smoking cessation programs. 31, 2010) . Subjects were included if they had : 1) ≥ 2 FSC prescription claims prior to the index (step-down) date; 2) ≥ 1 asthma claim [ICD-9-CM] codes 493.xx); 3) 12-64 years of age; and 4) continuously eligible for 12 months pre and post index. Subjects were excluded if they had: 1) COPD diagnosis (ICD-9 codes 491.xx, 492, xx, 496.xx), or 2) ≥ 1 prescription claim for anti-cholinergics or 3) receipt of higher dose FSC or another asthma controller other than FSC or ICS after the index.
PRS52 DEMOGRAPHIC CHARACTERISTICS OF ASTHMA SUBJECTS THAT STEP-DOWN FROM FLUTICASONE PROPIONATE-SALMETEROL COMBINATION THERAPY
Step-down was defined as reduction in dose of FSC (lower dose FSC) or moving to ICS only without the LABA (ICS monotherapy). These two cohorts were matched 1:3 with subjects that remained on the starting FSC dose (same dose FSC). Patient demographics included comorbidity, albuterol use, asthma-related health care utilization, number of controllers, number oral corticosteroids, number of physician visits, specialist visits, season, time to stepdown and FSC fill rate. Multivariate analysis was performed to determine the characteristics related to each step-down. RESULTS: Presence of a specialist visit [adjusted Odds Ratio (OR) 1.92, 95% CI 1.77-2.52 and OR 1.47, 95% CI 1.31-1.85] and more physician visits (OR=1.16, 95% CI: 1.11-1.28, and OR, 1.17 95% CI 1.11-1.28) prior to step-down were significantly associated with step-down of therapy for both low dose FSC (n=1,459), and ICS monotherapy (n=1,775) respectively. CONCLUSIONS: Subjects with close assessment of asthma disease and specialist care may be more likely to step-down from FSC therapy.
PRS53 UTILIZATION PATTERN OF RESPIRATORY MEDICATIONS AMONG CHRONIC OBSTRCTIVE PULMONARY DISEASE PATIENTS IN TAIWAN
Lin HW 1 , Yu IW 2 , Cheng WE 2 1 China Medical University, Taichung, Taiwan, 2 China Medical University Hospital, Taichung, Taiwan OBJECTIVES: Incidence of chronic obstructive pulmonary disease (COPD) has increased globally. The respiratory medications were the main treatment strategies to control for COPD disease progression. The purpose of the current study was to explore the utilization pattern of respiratory medications among COPD patients in Taiwan. METHODS: A retrospective observational study was conducted by using 2000 and 2005 Longitudinal Health Insurance Databases (two million random samples). A cohort of national health insurance beneficiaries with any newly diagnosis for COPD (International Classification of Diseases, codes=491.x, 492.x, 496) in 2006 and aged greater than 40-year-old was identified. These COPD patients were assessed and followed for one-year from the date of their first prescription of any inhaled COPD medications (index date) and their persistence of each class of COPD medications was evaluated. RESULTS: A cohort of 7838 new COPD cases was identified in 2006. They were about 68.9±12.6 years old and male was predominant (67%). Of all, 95% were coded with 496. However, only 579(6.9%) were ever prescribed with inhaled COPD medications in 2006. The days to the first prescription of inhaled COPD medications after diagnosis were 26 days in average, and up to 336 days. Only 5.5% to 19% of patients continued on the index drug for more than 6 months, which decreased to 1 to 5% at 12 months. The long-acting muscarinic antagonist (LAMA) showed the highest persistence among the other medications, whereas inhaled corticosteroid (ICS) had the lowest. CONCLUSIONS: Respiratory medications were obviously under-utilized in Taiwanese patients with COPD. Further study is needed to explore the consequence of such phenomenon and its potential resolutions.
PRS54 PRESCRIBING LONG-ACTING BETA-AGONISTS AS MONOTHERAPY TO ADULTS WITH CONTROLLED AND UNCONTROLLED ASTHMA
Ali AK 1 , Hartzema AG 2 1 Eli Lilly and Company, Indianapolis, IN, USA, 2 University of Florida, Gainesville, FL, USA OBJECTIVES: To describe demographic and health care utilization characteristics of adults with asthma who initiated inhaled long-acting beta-agonist (LABA) bronchodilators as monotherapy. METHODS: A cohort of asthmatic adults with controlled and uncontrolled asthma in the General Practice Research Database was retrospectively followed to compare the propensity of initiating inhaled LABA monotherapy versus any other inhaled controller medication_inhaled corticosteroids (ICS) monotherapy or ICS/LABA combination therapy. Patients with controlled asthma are defined as not having >2 asthma drug classes or any short-acting beta-agonists (SABA) prescribed at the LABA prescribing date; and not having any of the following during 12 months before LABA prescribing date: prescription for oral corticosteroids, >6 prescriptions for SABA, or attending emergency departments or hospitalization for asthma. RESULTS: Among the 51,103 patients aged 13-65 who met the inclusion criteria, 60% were uncontrolled asthmatics and 40% had controlled asthma. the majority of patients in both groups were nonsmoking obese females who visited general practices in England. Patients with controlled asthma were more likely to receive LABA monotherapy than patients with uncontrolled asthma (OR=2.22, 95%CI=1.90-2.59). Asthmatics who were prescribed leukotriene receptor antagonists (LTRA) were at risk of receiving add-on LABA (OR=7.90, 95%CI=4.27-13.53). General practices in England were less likely to prescribe LABA monotherapy than practices in Scotland, Wales, or Northern Ireland. Consultations ≤10 minutes were associated with 38% higher likelihood of prescribing LABA monotherapy inhalers than visits with longer duration. CONCLUSIONS: Adults with controlled asthma who are ICS-naïve are more likely to initiate LABA monotherapy than patients with uncontrolled asthma; however, LABA is prescribed as an add-on therapy to anti-inflammatory LTRA in controlled asthmatics.
PRS55 RACIAL AND ETHNIC DISPARITY IN SMOKING CESSATION MEDICATION USE AMONG ADULT SMOKERS IN THE UNITED STATES
Wang X 1 , Abughosh S 2 1 Universtiy of Houston, Houston, TX, USA, 2 University of Houston, Houston, TX, USA OBJECTIVES: To examine racial/ethnic disparity in smoking cessation medication use among adult smokers in the United States. METHODS: A retrospective cross-sectional study was conducted using the Medical Expenditure Panel Survey (MEPS) data (2009). The study included adults aged ≥ 18 years who self-reported currently using tobacco. The outcome variable was receiving smoking cessation medication use versus not. Andersen's Behavioral Model of Health Services Utilization was used as the conceptual framework. The independent variables were categorized into predisposing, enabling, and need characteristics, including age, gender, race, marital status, education, insurance status, family income, region, urban residence, usual source of health care, general health status, comorbidity, obesity, activities of daily living. Descriptive statistics and chi-square tests were used to examine group differences. Multivariate logistic regression analysis was performed to investigate racial/ethnic disparity in smoking cessation medication use. RESULTS: Total sample was 39,900,131and mostly comprised of Non-Hispanic Whites (73.38%), followed by Non-Hispanic Black (12.20%), Hispanics (9.53%), and others (4.88%). Race was a significant predictor of smoking cessation medication use. The findings indicated that Non-Hispanic Blacks were less likely to use smoking cessation medication compared to Non-Hispanic Whites (odds ratio [OR]: 0.39, 95% confidence interval [CI]: 0.19-0.80). Smokers who live in South were less likely to use smoking cessation medication compared with those who live in Northeast (OR: 0.43, 95% CI: 0.20-0.93). Obese people were more likely to use smoking cessation medication compared to non-obese smokers (OR: 2.68, 95% CI: 1. 69-4.27) . Additionally, urban residence was a significant predictor of smoking cessation medication use (OR: 2.26, 95% CI: 1.17-4.39). CONCLUSIONS: While smoking cessation remains highly recommended for all smokers, Black smokers are less likely to use smoking cessation medications compared to White. Further research is needed to understand the reasons for this disparity and find ways to eliminate it. Bashaar M, Hassali MA Universiti Sains Malaysia, Penang, Malaysia OBJECTIVES: The current study is aimed to assess the knowledge and perceptions of physicians towards medicine quality and prices in Kabul City. METHODS: In this cross-sectional descriptive survey, a total of 400 physicians were approached to be part of the survey and 347 consented to participate (response rate of 86.7%). RESULTS: In the survey, 36.6% of physicians felt that the quality of imported medicine is good, and 50.8% often felt that medicines given by public hospitals are of high quality. However 40.6% disagreed that the Afghan Drug Regulatory Authority controls quality of medicine registered in the country. Overall, 85.6% of respondents felt that the government should adopt health policies to control the medicine prices and expenditures, and 76.3% reported that higher medicine costs negatively impacts patient outcomes. Only 45% reported that doctors have poor understandings on medicine prices, and 84.5% reported that the medicine prices both in the government and private should be made public. Among the respondents, 26.3% felt that medicine prices are affordable to their patients. A high proportion of the respondents (85.2%) agreed that prescription medicine prices must be regulated by the government since 70.3% of physicians reported that medicine prices are high in private hospitals. About 60.5% of the physicians felt that medicine prices influence their prescribing decision, and 65.8% agreed that the patient's income influences their prescribing decisions. CONCLUSIONS: Results suggest that physicians must be costconscious and alert in their prescriptions and do not undermine the cost of medication. As a conclusion, the Afghan Drug Regulatory Authority should control the medicine prices and quality on a regular basis in the market, which will act as leverage for sustainable and effective treatment and access to essential medicines. Further, the study suggests that there is substantial room for improvement in the knowledge of physicians about medicine quality and prescription cost.
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ASSESSMENT OF PHYSICIANS' KNOWLEDGE AND PERCEPTIONS TOWARDS MEDICINE QUALITY AND PRICES IN KABUL, AFGHANISTAN
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COMPARISON OF DIAGNOSIS BASED COMORBIDITY INDICES TO PREDICT HIGH COST COPD PATIENTS PROSPECTIVELY
Mhatre SK, Aparasu RR, Johnson ML University of Houston, Houston, TX, USA OBJECTIVES: High health care costs are incurred by Chronic Obstructive Pulmonary Disease (COPD) patients. Identifying high cost patients prospectively benefits health care providers and insurance companies. The purpose of the current study was to compare the performance of generic and COPD specific diagnosis based comorbidity measures in predicting high medical expenditures in COPD patients. METHODS: A longitudinal study was conducted using nationally representative data from the Medical Expenditure Panel Survey. Prediction models were developed using cohorts initiated in 2008-2009 and validated using cohorts initiated in 2006-2007. Logistic regression was used to predict being in the upper expenditure decile in year 2, using data from year 1. Three comorbidity measures were compared: D'Hoore Charlson comorbidity index, Elixhauser comorbidity index and COPD specific comorbidity Test (COTE). Models were evaluated using c-statistics, Hosmer-Lemeshow statistic, correlation coefficient and positive prediction value. RESULTS: Comorbidity indices improved prediction of high cost COPD patients beyond age and gender, with the Elixhauser index providing the best prediction (c-statistic: 0.82), followed by COTE (c-statistic: 0.74). The Hosmer-Lemeshow test for both was also non-significant, indicating high accuracy. The COTE index had the best external validation properties (c-statistics: 0.66, Hosmer-Lemeshow: 7.4), followed by Elixhauser index (c-statistics: 0.61, Hosmer-Lemeshow: 12.1). In both learning and testing models, the difference in c-statistics of Elixhauser and COTE models was non-significant (learning, z=1.53 and testing, z=0.12), indicating that both measures do not differ in their discriminative power. CONCLUSIONS: Both, Elixhauser index and the COPD specific COTE index can best predict high costs in COPD patients and inclusion of either of them in risk adjustment models will be valuable in managing high cost COPD patients.
